Truist Securities acted as exclusive financial advisor to Emergent BioSolutions. Emergent BioSolutions (NYSE:EBS) announced the sale of its Baltimore-Camden sterile drug product facility to Bora Pharmaceuticals (TWSE:6472) for $30M. The Baltimore-Camden facility provides drug product manufacturing services for sterile injectables and offers clinical and commercial non-viral, aseptic fill/finish services to third-party customers. Congratulations to both teams on this exciting transaction.
Braden Willis’ Post
More Relevant Posts
-
Check out the Leading Pharmaceutical Companies Worldwide Based on 2023 Sales 2023 Pharma Industry Leaders: Johnson & Johnson leads with $85.16 Bn in sales, followed by Merck at $53.5 Bn. With the industry valued at US$1.48 Tn in 2022, #pharmaceutical companies continue to thrive amidst challenges, showcasing resilience, innovation, and market growth through novel drug developments. #noveldrugs #companies #healthcareindustry #insights10
To view or add a comment, sign in
-
-
Check out some news from two iBIO Members!
iBIO Members Partner for Growth: Eli Lilly Bolsters Manufacturing with Acquisition of Nexus’ Wisconsin Plant Great news for the biopharma industry! iBIO member Eli Lilly has announced a strategic acquisition to boost its injectable drug manufacturing capabilities. As highlighted in today's iBIO NewsBrief, Lilly is acquiring an 84,000-square-foot FDA-approved facility in Pleasant Prairie, Wisconsin, from fellow iBIO member Nexus Pharmaceuticals. This strategic move will allow Lilly to dedicate the entire plant to the production of its injectable medications, addressing the surging demand for these vital treatments. Want to learn more? Read the full article in iBIO NewsBrief https://lnkd.in/gayQkUpm Subscribe to stay up-to-date on industry developments! https://lnkd.in/g58aVNUw #ibio #manufacturing #partnership #growth #injectabledrugs #pharmaceuticals #wisconsin
To view or add a comment, sign in
-
-
In a highly anticipated deal between the British government, NHS England, and the Association of the British Pharmaceutical Industry (ABPI), the 2024 voluntary scheme for branded medicines pricing, access and growth was just announced. Innovation is rewarded by increasing the allowed annual growth rate for branded drugs to 4 percent (vs. 2% currently) and requiring an additional rebate rate of up to 25% for older drugs (on top of the 10% base rebate). Seen by some as another example for margin pressures in region Europe, and regarded by others as a measure aimed at rewarding innovation, biopharmaceutical manufacturers ought to invest early in strategic assessments of the pricing potential of their innovative portfolios. #ABPI #unitedkingdom #drugpricing #nhsengland #healthcarepolicy https://lnkd.in/eRe8RKkx.
To view or add a comment, sign in
-
Provider institutions and pharmaceutical companies can be frenemies or adversaries, but the acrimony isn't working for anyone, especially patients. There is a better way to collaborate, where both stakeholders bring their needs and capabilities to develop common goals. But how do we get there? Pharmaceutical companies can forge meaningful relationships with providers by leveraging Key Account Managers (KAMs). Four strategic areas where KAMs can play a pivotal role in turning the current situation from a lose-lose-lose proposition to one where providers, pharmaceutical companies, and patients all win > https://owy.mn/4cWvUr1 #OWHealth #healthcare #pharma
To view or add a comment, sign in
-
Pharmaceutical companies are uniquely positioned to make a difference by partnering with Integrated Delivery Networks (IDNs). These networks are all about enhancing patient care while keeping costs down. By sharing data and working together, pharmaceutical companies can tailor their drug development to directly address patient needs. This approach is a win-win; it isn't just good for patients, it's smart business. Interested in how these partnerships work and their benefits? Dive into the details here: https://lnkd.in/ewj-Mjv2
To view or add a comment, sign in
-
-
In the third quarter of 2023, the pharmaceutical industry experienced a significant increase in the use of big data, with a 25% growth compared to the same time in 2022. Compared to the previous quarter, there was an even bigger jump of 82% in deal activities during Q3 2023. Top pharmaceutical companies like Johnson & Johnson, Bristol Myers Squibb, Merck, AstraZeneca, and Pfizer are leading the way in utilizing big data. Let's explore how these companies and others are using big data analytics to change the operational dynamics of the pharmaceutical industry. https://lnkd.in/eQV6ZmAj
To view or add a comment, sign in
-
In Grandstream Networks latest case study, this pharmaceutical company had a number of network limitations that were solved by switching to their GWN series of Wi-Fi access points. Learn how Grandstream created a scalable, high-speed, and reliable network here: https://lnkd.in/egW7wXbC #ntsdirect #GWN7660 #GWN7630 #GWNCloud
GlaxoSmithKline Wi-Fi Solution
blog.grandstream.com
To view or add a comment, sign in
-
🚀 Adapting to Change: The Evolution of Pharmaceutical Outsourcing 🚀 In an ever-evolving pharmaceutical landscape, outsourcing strategies have become indispensable for drugmakers and biotechs. With an increasing number of companies delegating aspects of their operations, the partnerships between contracted organizations and drug sponsors are dynamically shifting to align with evolving priorities. The future of pharmaceutical outsourcing is marked by constant change, demanding the industry's adeptness in adapting and evolving to meet emerging challenges head-on. Our latest Trend Report delves into this transformative journey, shedding light on how strategies for both drug sponsors and vendors are evolving to navigate the demands of an evolving world. Stay informed and stay ahead of the curve with our comprehensive report! #Pharma #CPHIOnline https://ow.ly/qoEA50RzyX7
To view or add a comment, sign in
-
-
Join our exclusive discussion on the drugs set to dominate headlines in 2024! Gain invaluable insight into how the #pharmaceutical market will evolve over the next 12 months and its impact on long-term industry trends. Register today: https://lnkd.in/gyvBRAdB Sponsored by Avalere Health #biopharma #pharmaceuticals #pharmainsights #pharmatrends
Drugs That Will Shape 2024
us02web.zoom.us
To view or add a comment, sign in
-
📢 Delve into the Insights of Bulgaria's Pharmaceutical Industry and Media Landscape 💊📰 Our latest report on the pharmaceutical industry in Bulgaria and its intricate media landscape provides a comprehensive look into the critical findings shaping this dynamic sector. Join us as we unveil the essential discoveries that can impact the future of healthcare and media trends and get all the details from the full report here 👉 https://lnkd.in/dgWQCJr2 #pharmaindustry #mediamonitoring #socialmedialistening #bigdata #perceptica
To view or add a comment, sign in